Table 4. – Impact of groups defined by changes in MR severity: baseline to discharge, discharge to follow-up, and general mortality.
| Mean time (months | Deaths (%) | Non-adjusted | Adjusted** | |||
|---|---|---|---|---|---|---|
|
| ||||||
| HR (95% CI) | p value* | HR (95% CI) | p value* | |||
| MR from baseline to discharge | ||||||
| Unchanged (reference) | 54.6 | 24,5 | 1 | 1 | ||
| Worsening | 44.0 | 28.6 | 1.21 (0.68 – 2.14) | 0.512 | 1.28 (0.70–2.32) | 0.426 |
| Improvement | 35.1 | 25.0 | 1.03 (0.61 – 1.73) | 0.912 | 1.17 (0.69–1.98) | 0.561 |
| MR from discharge to follow-up | ||||||
| Unchanged (reference) | 68.1 | 16.9 | 1 | 1 | ||
| Worsening | 51.3 | 28.2 | 1.61 (0.85 – 3.04) | 0.141 | 2.74 (1.36 – 5.48) | 0.005 |
| Improvement | 50.5 | 18.8 | 1.42 (0.62 – 3.29) | 0.408 | 1.48 (0.62 – 3.50) | 0.377 |
*Cox regression model (stepwise backward likelihood ratio ) and Wald test, p < 0.05. **Baseline-to-discharge mitral dysfunction: adjusted for baseline hemoglobin level, NYHA functional class and previous balloon aortic valvuloplasty; **Discharge-to-follow-up mitral dysfunction: adjusted for NYHA functional class and previous balloon aortic valvuloplasty. CI: confidence interval, HR: hazard ratio, MR: mitral regurgitation.